Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Immunoglobulin Light-chain Amyloidosis 1Head and Neck Neoplasms 1Amyloidosis 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × In Situ Hybridization × Clear all
NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT00498953 2018-07-09

Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1/2 Completed
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡